Plant Name: Artemisia scoparia
Taxonomic Information:
Plant ID: NPO18681
Plant Latin Name: Artemisia scoparia
Taxonomy Genus: Artemisia
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
72351
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Antibacterial; Anticholesterolemic; Antipyretic; Antiseptic; Cholagogue; Diuretic; Vasodilator
Geographical Distribution:
India; China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; | |
| TSHR; | |
| PTPN1; | |
| TDP1; BLM; AKR1B1; GFER; HSD17B10; ALOX15; AKR1B10; ALDH1A1; | |
| TRPA1; | |
| MAPK1; PIM1; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA13; CA5A; CA7; CA3; CA14; CA5B; CA6; | |
| ESR1; ESR2; | |
| PTGS1; | |
| MMP9; MMP1; MMP2; | |
| CASP1; CASP7; | |
| HIF1A; NFKB1; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.031E-13 | 5.529E-10 | BLM, CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.545E-08 | 5.514E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.767E-07 | 2.405E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.241E-07 | 2.572E-04 | BLM, CA2, CA9, CASP1, CASP7, CSNK2A1, CYP1A2, ESR1, MAPK1, NFKB1, TRPA1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.229E-27 | 2.676E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.927E-06 | 1.399E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.927E-06 | 1.399E-03 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.396E-06 | 2.901E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 9.845E-06 | 5.878E-03 | AKR1B1, ALOX15, BLM, CA2, CA9, HIF1A, LMNA, MAPK1, MAPT, MMP9, NFKB1, PTPN1, TDP1 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.215E-05 | 6.616E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.272E-05 | 6.753E-03 | AKR1B1, AKR1B10, CYP1A2, CYP2C9, CYP3A4, ESR1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 6.828E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.750E-05 | 8.660E-03 | AKR1B1, BLM, CASP7, MAPK1, MMP2, NFKB1, TSHR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.626E-21 | 7.214E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.380E-19 | 7.513E-16 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.630E-05 | 1.193E-02 | ESR1, ESR2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.579E-27 | 1.099E-24 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA7, CA6, CA9, CA14, CA13 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.478E-07 | 2.521E-05 | CYP2C9, CYP1A2, ALOX15, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.457E-06 | 6.330E-05 | MMP1, MMP2, MAPK1, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.746E-06 | 6.330E-05 | MMP2, MAPK1, ESR1, MMP9, ESR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.414E-05 | 3.416E-04 | MAPK1, ESR1, NFKB1, ESR2 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 9.399E-06 | 2.726E-04 | CYP2C9, CYP1A2, ALDH1A1, CYP3A4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 5.374E-05 | 9.199E-04 | MMP2, PIM1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.710E-05 | 9.199E-04 | MMP2, MAPK1, HIF1A, ESR1, MMP9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.663E-05 | 3.444E-04 | CASP7, CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.471E-04 | 1.778E-03 | MMP1, MMP2, MAPK1, HIF1A, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 7.499E-05 | 1.060E-03 | CASP7, MAPK1, MMP9, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 8.044E-05 | 1.060E-03 | CYP2C9, ALOX15, MAPK1, PTGS1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.905E-04 | 1.963E-03 | CASP7, LMNA, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.167E-04 | 1.963E-03 | PIM1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.948E-04 | 1.963E-03 | CASP7, CASP1, NFKB1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 3.818E-04 | 2.913E-03 | CASP7, MAPK1, MAPT, HSD17B10 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.780E-04 | 2.372E-03 | CYP2C9, ALOX15, PTGS1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.167E-04 | 1.963E-03 | CASP1, MAPK1, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.532E-04 | 4.551E-03 | CYP2C9, AKR1B10, CYP1A2, ALOX15, ALDH1A1, AKR1B1, CYP3A4, HSD17B10, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.814E-04 | 2.913E-03 | CYP2C9, CYP1A2, CYP3A4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.685E-04 | 3.235E-03 | PTPN1, CSNK2A1, MAPK1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.502E-04 | 3.235E-03 | CYP2C9, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.227E-03 | 7.115E-03 | MAPK1, HIF1A, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.328E-04 | 4.171E-03 | CYP2C9, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 7.272E-04 | 4.551E-03 | CASP1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.812E-03 | 9.733E-03 | MAPK1, ESR1, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.902E-03 | 9.780E-03 | ADORA3, MAPK1, NFKB1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.720E-03 | 9.592E-03 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 1.956E-03 | 9.780E-03 | AKR1B10, AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MAPK1; MMP2; CA9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; MMP9; MAPK1; MMP2; CA9; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
